Vivani Medical (VANI) 10-Q 15 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 10, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	SECOND SIGHT MEDICAL PRODUCTS INC
Entity Central Index Key	0001266806
Trading Symbol	eyes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		124,197,961
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 31,682	$ 4,471
Accounts receivable, net	597	504
Inventories, net	1,602	3,250
Prepaid expenses and other current assets	1,155	1,395
Total current assets	35,036	9,620
Property and equipment, net	963	1,025
Right-of-use assets	2,508
Deposits and other assets	41	37
Total assets	38,548	10,682
Current liabilities:
Accounts payable	1,600	1,305
Accrued expenses	2,309	2,503
Accrued compensation expense	2,080	2,690
Accrued clinical trial expenses	1,016	933
Current operating lease liabilities	210
Contract liabilities	218	167
Total current liabilities	7,433	7,598
Long term operating lease liabilities	2,586
Total liabilities	10,019	7,598
Commitments and contingencies
Stockholders’ equity:
Preferred stock, no par value, 10,000 shares authorized; none outstanding
Common stock, no par value; 200,000 shares authorized; shares issued and outstanding: 124,198 and 76,336 as of March 31, 2019 and December 31, 2018, respectively	263,418	229,019
Additional paid-in capital	46,586	44,111
Accumulated other comprehensive loss	(583)	(575)
Accumulated deficit	(280,892)	(269,471)
Total stockholders’ equity	28,529	3,084
Total liabilities and stockholders’ equity	$ 38,548	$ 10,682

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred stock, no par value (in dollars per share)
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, no par value (in dollars per share)
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	124,198,000	76,336,000
Common stock, shares outstanding (in shares)	124,198,000	76,336,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Net sales	$ 1,128	$ 976
Cost of sales	731	668
Gross profit	397	308
Operating expenses:
Research and development, net of grants	2,183	2,474
Clinical and regulatory	1,006	1,348
Selling and marketing	2,103	3,011
General and administrative	2,449	3,244
Impairment charge	2,424
Total operating expenses	10,165	10,077
Loss from operations	(9,768)	(9,769)
Interest income	68	16
Net loss	$ (9,700)	$ (9,753)
Net loss per common share – basic and diluted	$ (0.10)	$ (0.17)
Weighted average common shares outstanding – basic and diluted	96,567	59,052

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (9,700)	$ (9,753)
Other comprehensive income (loss):
Foreign currency translation adjustments	(8)	45
Comprehensive loss	$ (9,708)	$ (9,708)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Common Stock Issuable [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance beginning at Dec. 31, 2017	$ 7,882	$ 202,156	$ 153	$ 40,522	$ (572)	$ (234,377)
Balance beginning (in shares) at Dec. 31, 2017		57,630,000	82,000
Issuance of shares of common stock, net of issuance costs	3,992	$ 3,992
Issuance of shares of common stock, net of issuance costs (in shares)		2,224,000
Warrants exercise	7	$ 7
Warrants exercise (in shares)		5,000
Common stock issuance for services	65		$ 65
Common stock issuance for services (in shares)			34,000
Release of restricted stock units (in shares)		12,000
Stock-based compensation expense	1,285			1,285
Exercise of common stock options	8	$ 8
Exercise of common stock options (in shares)		5,000
Net loss	(9,753)					(9,753)
Foreign currency translation adjustment	45				45
Balance ending at Mar. 31, 2018	3,531	$ 206,163	$ 218	41,807	(527)	(244,130)
Balance ending (in shares) at Mar. 31, 2018		59,876,000	116,000
Balance beginning at Dec. 31, 2018	$ 3,084	$ 229,019		44,111	(575)	(269,471)
Balance beginning (in shares) at Dec. 31, 2018	76,336,000	76,336,000
Adoption of ASC Topic 842-Leases (see note 2) at Dec. 31, 2018	$ (144)					(144)
Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs	34,399	$ 34,399
Issuance of shares of common stock and warrants in connection with rights offering, net of issuance costs (in shares)		47,812,000
Release of restricted stock units (in shares)		50,000
Warrants modification (see note 7)				1,577		(1,577)
Stock-based compensation expense	898			898
Net loss	(9,700)					(9,700)
Foreign currency translation adjustment	(8)				(8)
Balance ending at Mar. 31, 2019	$ 28,529	$ 263,418		$ 46,586	$ (583)	$ (280,892)
Balance ending (in shares) at Mar. 31, 2019	124,198,000	124,198,000

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (9,700)	$ (9,753)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	99	111
Stock-based compensation	898	1,285
Non-cash lease expense	6
Inventory reserve		(109)
Impairment charge	2,424
Common stock issuance for services		65
Changes in operating assets and liabilities:
Accounts receivable	(95)	1,374
Inventories	(786)	21
Prepaid expenses and other assets	236	(16)
Accounts payable	297	857
Accrued expenses	(57)	(354)
Accrued compensation expenses	(609)	(534)
Accrued clinical trial expenses	84	161
Contract liabilities	53	114
Net cash used in operating activities	(7,150)	(6,778)
Cash flows from investing activities:
Purchases of property and equipment	(37)	(68)
Net cash used in investing activities	(37)	(68)
Cash flows from financing activities:
Net proceeds from sale of common stock and warrants	34,399	3,992
Proceeds from exercise of options and warrants		15
Net cash provided by financing activities	34,399	4,007
Effect of exchange rate changes on cash and cash equivalents	(1)	14
Cash and cash equivalents:
Net increase (decrease)	27,211	(2,825)
Balance at beginning of period	4,471	7,839
Balance at end of period	$ 31,682	$ 5,014

Organization and Business Opera

Organization and Business Operations	3 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Business Operations	1. Organization and Business Operations Second Sight Medical Products, Inc. (“Second Sight,” “we,” “us,” or “the Company”) was incorporated in the State of California in 2003. Second Sight develops, manufactures and markets implantable visual prosthetics to enable blind individuals to achieve greater independence. In 2007, Second Sight formed Second Sight Medical Products (Switzerland) Sàrl, initially to manage clinical trials for its products in Europe, and later to manage sales and marketing in Europe, the Middle East and Asia-Pacific. As the laws of Switzerland require at least two corporate stockholders, Second Sight Medical Products (Switzerland) Sàrl is 99.5% owned directly by us and 0.5% owned by an executive of Second Sight as of March 31, 2019. Accordingly, Second Sight Medical Products (Switzerland) Sàrl is considered 100% owned for financial statement purposes and is consolidated with Second Sight for all periods presented. We are currently developing the Orion ® Our commercial product, the Argus ® Liquidity and Going Concern From inception, our operations have been funded primarily through the sales of our common stock and warrants, as well as from the issuance of convertible debt, research and clinical grants, and limited product revenue generated from the sale of our Argus II product. Funding of our business since 2018 has been provided by: • Issuance of common stock through our At Market Issuance Sales Agreement (the “Sales Agreement”) • Issuance of common stock in a securities purchase agreement in May 2018, which provided net cash proceeds of $10.0 million. • Issuance of common stock in a securities purchase agreement in August 2018, which provided net cash proceeds of $5.0 million. • Issuance of common stock in a securities purchase agreement in October 2018, which provided net cash proceeds of $4.0 million. • Issuance of common stock in a securities purchase agreement in December 2018, which provided net cash proceeds of $3.0 million. • Issuance of common stock and warrants in a rights offering in February 2019, which provided net cash proceeds of $34.4 million. • Revenue of $1.1 million for the three months ended March 31, 2019 and $6.9 million for the year ended December 31, 2018 generated by sales of our Argus II product. In November 2017, we entered into an At Market Issuance Sales Agreement with B. Riley FBR Inc. and H.C. Wainwright & Co., LLC, as agents (“Agents”) pursuant to which we may offer and sell, from time to time through either of the Agents, shares of our common stock having an aggregate offering price as set forth in the Sales Agreement and a related prospectus supplement filed with the SEC. We agreed to pay the Agents a cash commission of 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. During January and February 2018, we sold 2.2 million shares of common stock which provided net proceeds of $4.0 million under the Sales Agreement. No shares have been sold since February 2018 under the Sales Agreement. In a rights offering completed on February 22, 2019, we sold approximately 47.8 million units, each priced at $0.724 for gross proceeds of approximately $34.6 million. Each unit consisted of one share and one immediately exercisable warrant having an exercise price of $1.47 per share. Entities controlled by Gregg Williams, our Chairman of the Board of Directors, acquired approximately 41.4 million units in the offering for an aggregate investment of approximately $30 million. On January 25, 2019, we received a letter from The Nasdaq Stock Market advising us that for 30 consecutive trading days preceding the date of the letter, the bid price of our common stock had closed below the $1.00 per share minimum required for continued listing on The Nasdaq Capital Market pursuant to listing rules, and therefore we could become subject to delisting if we did not regain compliance within the compliance period (or the compliance period as may be extended). We continue to monitor and evaluate our options to cure this deficiency within the compliance period. Our financial statements have been presented on the basis that our business is a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We are subject to the risks and uncertainties associated with a business with one product line and limited commercial product revenues, including limitations on our operating capital resources and uncertain demand for our products. We have incurred recurring operating losses and negative operating cash flows since inception, and we expect to continue to incur operating losses and negative operating cash flows for the foreseeable future. We do not have sufficient funds to support our operations for the next 12 months from the date of issuance of these financial statements. Accordingly, these and other related factors raise substantial doubt about our ability to continue as a going concern. We anticipate that we will seek to additionally fund our operations through public or private equity or debt financings, grants, collaborations, strategic partnerships or other sources. However, we may be unable to raise additional capital or enter into such other arrangements when needed on favorable terms or at all. If we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or any other approved product candidates, or we may be unable to expand our operations, maintain our current organization and employee base or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and results of operations. The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

Basis of Presentation, Signific

Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements	2. Basis of Presentation, Significant Accounting Policies and Recent Accounting Pronouncements Basis of Presentation These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. Certain prior year amounts have been reclassified to conform to the current year presentation. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2018, contained in our Annual Report on Form 10-K filed with the SEC on March 18, 2019. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period. Significant Accounting Policies Discontinued operations Based upon our decision on May 10, 2019 to accelerate our transition to the Orion platform, we evaluated our accounting policies related to the disposition in accordance with ASC 205-20 Discontinued Operations Property, Plant, and Equipment Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2018. Recently Adopted Accounting Pronouncements We adopted ASU No. 2016-02— Leases (Topic 842) We do not believe that any other recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

Concentration of Risk

Concentration of Risk	3 Months Ended
	Mar. 31, 2019
Risks And Uncertainties [Abstract]
Concentration of Risk	3. Concentration of Risk Credit Risk Financial instruments that subject us to concentrations of credit risk consist primarily of cash, money market funds, and trade accounts receivable. We maintain cash and money market funds with financial institutions that we deem reputable. We extend differing levels of credit to our customers, and typically do not require collateral. Customer Concentration The following tables provide information about disaggregated revenue by service type, customer and geographical market. The following table shows our revenues by customer type during the three months ended March 31, 2019 and 2018: Three Months Ended March 31, 2019 2018 Direct channel $ 946 $ 659 Indirect channel 182 317 $ 1,128 $ 976 During the three months ended March 31, 2019 and 2018, the following customers each comprised greater than 10% of our total revenues : Three Months Ended March 31, 2019 2018 Customer 1 23 % 15 % Customer 2 15 % 14 % Customer 3 13 % — % Customer 4 12 % — % Customer 5 12 % — % Customer 6 10 % 11 % Customer 7 10 % — % Customer 8 — % 22 % Customer 9 — % 12 % Customer 10 — % 11 % As of March 31, 2019 and December 31, 2018, the following customers each comprised greater than 10% of our total accounts receivable: March 31, 2019 December 31, 2018 Customer 1 28 % — % Customer 2 24 % 22 % Customer 3 23 % 21 % Customer 4 22 % — % Customer 5 — % 55 % Geographic Concentration During the three months ended March 31, 2019 and 2018, regional revenue based on customer locations which each comprised greater than 10% of our total revenues, consisted of the following : Three Months Ended March 31, 2019 2018 United States 60 % 53 % Italy 23 % 15 % Korea 10 % 11 % Singapore — % 12 % Foreign Operations The accompanying condensed consolidated financial statements as of March 31, 2019 and December 31, 2018 both include assets amounting to $1.5 million

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The authoritative guidance with respect to fair value establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that we have the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. Cash equivalents which includes money market funds are the only financial instrument measured and recorded at fair value on our consolidated balance sheet, and they are valued using Level 1 inputs. Assets measured at fair value on a recurring basis are as follows (in thousands): Total Level 1 Level 2 Level 3 March 31, 2019 (unaudited): Money market funds $ 31,335 $ 31,335 $ — $ — December 31, 2018: Money market funds $ 4,156 $ 4,156 $ — $ — As of March 31, 2019 and December 31, 2018, the money market funds include $0.2 million held in a deposit account in Switzerland as security for the performance of contracts.

Selected Balance Sheet Detail

Selected Balance Sheet Detail	3 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Selected Balance Sheet Detail	5. Selected Balance Sheet Detail Inventories, net Inventories consisted of the following (in thousands): March 31, December 31, 2019 2018 Raw materials $ 791 $ 791 Work in process 2,512 3,055 Finished goods 2,705 2,089 6,008 5,935 Allowance for excess and obsolete inventory and impairment charge (4,406 ) (2,685 ) Inventories, net $ 1,602 $ 3,250 We recorded $2.4 million as an impairment charge in the first quarter of 2019, related to our plans to suspend Argus II production. See note 10 for further details. Property and equipment Property and equipment consisted of the following (in thousands): March 31, December 31, 2019 2018 Laboratory equipment $ 2,482 $ 2,482 Computer hardware and software 1,493 1,456 Leasehold improvements 298 298 Furniture, fixtures and equipment 46 46 4,319 4,282 Accumulated depreciation and amortization (3,356 ) (3,257 ) Property and equipment, net $ 963 $ 1,025 Contract Liabilities Contract liabilities consisted of the following (in thousands): Beginning balance as of December 31, 2018 $ 167 Consideration received in advance of revenue recognition 51 Revenue recognized — Ending Balance as of March 31, 2019 $ 218 Allowance for Doubtful Accounts Allowance for doubtful accounts consisted of the following (in thousands): Beginning balance as of December 31, 2018 $ 181 Additions — (Write-offs) Recoveries (1 ) Ending Balance as of March 31, 2019 $ 180 Right-of-use assets and operating lease liabilities We lease certain office space and equipment for our use. Leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease assets and liabilities consisted of the following (in thousands): Assets Classification March 31, Non-current assets Right-of-use assets $ 2,508 Liabilities Current Current operating lease liabilities $ 210 Long term Long term operating lease liabilities $ 2,586 : The components of lease expense for the three months ended March 31, 2019 were as follows (unaudited): For the three months ended Lease expense: Operating lease expense $ 123 Short-term lease expense — Total lease expense $ 123 Other information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 117 For operating lease: Weighted average remaining lease term (in years) 7.9 Weighted average discount rate 10 % Minimum future payments under the Company’s leases at March 31, 2019 and their application to the corresponding lease liabilities are as follows (unaudited): Discounted lease Payments due 2019 (remaining nine months) $ 155 $ 359 2020 237 491 2021 277 505 2022 322 521 2023 352 516 Thereafter 1,453 1,704 Total $ 2,796 $ 4,096

Equity Securities

Equity Securities	3 Months Ended
	Mar. 31, 2019
Stockholders Equity Note [Abstract]
Equity Securities	6. Equity Securities Potentially Dilutive Common Stock Equivalents As of March 31, 2019 and 2018, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive (in thousands). March 31, 2019 2018 Common stock warrants issued to underwriter of initial public offering 802 802 Common stock warrants issued in connection with March 2017 rights offering 13,647 13,647 Common stock warrants issued in connection with February 2019 rights offering 47,812 — Common stock options 8,587 7,921 Common stock issuable — 116 Restricted stock units 513 71 Employee stock purchase plan 451 229 71,812 22,786

Warrants

Warrants	3 Months Ended
	Mar. 31, 2019
Warrants And Rights Note Disclosure [Abstract]
Warrants	7. Warrants Warrants to purchase 47,812,371 shares of common stock with an exercise price of $1.47 per share were issued in the rights offering completed in February 2019. The warrants are listed for trading under the symbol “EYESW” on the NASDAQ Capital Market and expire on March 14, 2024. At the Company’s discretion, the warrants are redeemable on 30 days’ notice (i) if, after March 14, 2019, the shares of the Company’s common stock are trading at $2.94 for 15 consecutive trading days and (ii) if all of the independent directors vote in favor of redeeming the warrants. Holders may be able to sell or exercise warrants prior to any announced redemption date and the Company will redeem outstanding warrants not exercised by the announced redemption date for a nominal amount of $0.01 per Warrant. The net cash proceeds were allocated to the relative fair values of the common stock and warrants on the date of issuance resulting in an allocation of $0.47 per share to the common stock and $0.25 per share to the warrants. In calculating the fair value of the warrants using the Black-Scholes model, the assumptions included a risk free interest rate of 2.49%, expected volatility of 82% and expected life of 5.08 years, and a 0% dividend yield. We extended the term of 13,647,286 warrants issued in our March 2017 rights offering (“March 2017 warrants”) by approximately two years effective as of February 15, 2019 as part of our February 2019 rights offering. We determined the fair value of the March 2017 warrants immediately before and after the modification. The fair value of the March 2017 warrants after the modification was increased by approximately $1.6 million, resulting in an accounting adjustment to additional paid-in capital and accumulated deficit in the consolidated statements of shareholders’ equity. A summary of warrants activity for the three months ended March 31, 2019 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Warrants outstanding as of December 31, 2018 14,449 $ 2.01 3.10 Issued 47,812 1.47 Exercised — Forfeited or expired — Warrants outstanding as of March 31, 2019 62,261 $ 1.60 4.90 Warrants exercisable as of March 31, 2019 62,261 $ 1.60 4.90 The warrants outstanding as of March 31, 2019 had no intrinsic value.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	8. Stock-Based Compensation A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the three months ended March 31, 2019 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Options outstanding as of December 31, 2018 7,120 $ 3.83 6.81 Granted 2,103 $ 0.78 Exercised — $ Forfeited or expired (636 ) $ 3.99 Options outstanding as of March 31, 2019 8,587 $ 3.07 7.77 Options exercisable as of March 31, 2019 3,357 $ 5.26 5.76 The estimated aggregate intrinsic value of stock options exercisable as of March 31, 2019 was approximately $1,000. As of March 31, 2019, there was $4.4 million of total unrecognized compensation cost related to outstanding stock options that will be recognized over a weighted average period of 3.02 years. During the three months ended March 31, 2019, we granted stock options to purchase 2,102,862 shares of common stock to certain employees. The options are exercisable for a period of ten years from the date of grant at prices ranging from $0.69 to $0.87 per share, which was the fair value of our common stock on the respective grant dates. The options generally vest over a period of four years. The fair value of these options, calculated using the Black-Scholes option-pricing model, was determined to be $1.1 million ($0.45 to $0.57 per share) using the following assumptions: expected term of 6.02 to 6.08 years, volatility of 72.0%, risk-free interest rate of 2.51% to 2.63%, and expected dividend rate of 0.0%. The following table summarizes restricted stock unit (“RSU”) activity for the three months ended March 31, 2019 (in thousands, except per share data): Number of Shares Weighted Average Grant Date Fair Value Per Share Outstanding as of December 31, 2018 35 $ 12.43 Awarded 527 0.75 Vested and released (49 ) 3.66 Forfeited/canceled — — Outstanding as of March 31, 2019 513 $ 1.28 As of March 31, 2019, there was $0.6 million of total unrecognized compensation cost related to the outstanding RSUs that will be recognized over a weighted average period of 3.73 years. During the three months ended March 31, 2019, we awarded RSUs of 526,500 to certain employees. The RSUs generally vest over a four year period, and were awarded at the fair value of our common stock on the respective award dates. We adopted an employee stock purchase plan in June 2015 for all eligible employees. At March 31, 2019 the maximum number of shares that may be issued under the plan is 2,050,000. Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three months ended March 31, 2019 and 2018 was as follows (in thousands): Three Months Ended March 31, 2019 2018 Cost of sales $ 47 $ 65 Research and development 187 103 Clinical and regulatory 34 92 Selling and marketing 130 123 General and administrative 500 902 $ 898 $ 1,285

Litigation, Claims and Assessme

Litigation, Claims and Assessments	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Litigation, Claims and Assessments	9. Litigation, Claims and Assessments Twenty-two oppositions have been filed by third-parties in the European Patent Office each challenging the validity of a European patent owned or exclusively licensed by us. The outcome of the challenges is not certain. However, if successful, they may affect our ability to block competitors from utilizing some of our patented technology in Europe. We do not believe a successful challenge will have a material effect on our ability to manufacture and sell our products, or otherwise have a material effect on our operations. We are party to litigation arising in the ordinary course of business. It is our opinion that the outcome of such matters will not have a material effect on our results of operations.

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Event	10. Subsequent Event On May 10, 2019, we commenced a corporate restructuring plan to focus on development of Orion and other key research projects. Specifically, we will reduce expenses and personnel by 21 employees related to commercial activities and production for the Argus ® We expect to recognize approximately $0.7 million of pre-tax restructuring charges in the second quarter of fiscal year 2019 in connection with this restructuring, consisting of severance and other employee termination benefits, substantially all of which are expected to be settled in cash during the next two quarters of 2019. We also recorded $2.4 million as an impairment charge in the first quarter of 2019, related to our plans to suspend production of Argus II. The $2.4 million includes a non-cash impairment charge to our inventory. We determined that there was no impairment of any other assets.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Significant Accounting Policies	Basis of Presentation These unaudited interim financial statements have been prepared in accordance with United States generally accepted accounting principles (“GAAP”) and following the requirements of the United States Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by GAAP can be condensed or omitted. In our opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of our financial position and our results of operations and cash flows for periods presented. Certain prior year amounts have been reclassified to conform to the current year presentation. These statements do not include all disclosures required by GAAP and should be read in conjunction with our financial statements and accompanying notes for the fiscal year ended December 31, 2018, contained in our Annual Report on Form 10-K filed with the SEC on March 18, 2019. The results of the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.
Discontinued Operations	Discontinued operations Based upon our decision on May 10, 2019 to accelerate our transition to the Orion platform, we evaluated our accounting policies related to the disposition in accordance with ASC 205-20 Discontinued Operations Property, Plant, and Equipment Our significant accounting policies are set forth in Note 2 of the financial statements in our Annual Report on Form 10-K for the year ended December 31, 2018.
Recent Accounting Pronouncements	Recently Adopted Accounting Pronouncements We adopted ASU No. 2016-02— Leases (Topic 842) We do not believe that any other recently issued, but not yet effective, accounting standards, if adopted, will have a material effect on the financial statements.

Concentration of Risk (Tables)

Concentration of Risk (Tables)	3 Months Ended
	Mar. 31, 2019
Risks And Uncertainties [Abstract]
Schedules of Revenues by Customer Type	The following table shows our revenues by customer type during the three months ended March 31, 2019 and 2018: Three Months Ended March 31, 2019 2018 Direct channel $ 946 $ 659 Indirect channel 182 317 $ 1,128 $ 976
Schedule of Concentration of Risk	During the three months ended March 31, 2019 and 2018, the following customers each comprised greater than 10% of our total revenues : Three Months Ended March 31, 2019 2018 Customer 1 23 % 15 % Customer 2 15 % 14 % Customer 3 13 % — % Customer 4 12 % — % Customer 5 12 % — % Customer 6 10 % 11 % Customer 7 10 % — % Customer 8 — % 22 % Customer 9 — % 12 % Customer 10 — % 11 % As of March 31, 2019 and December 31, 2018, the following customers each comprised greater than 10% of our total accounts receivable: March 31, 2019 December 31, 2018 Customer 1 28 % — % Customer 2 24 % 22 % Customer 3 23 % 21 % Customer 4 22 % — % Customer 5 — % 55 %
Schedule of Geographic Concentration of Risk in Revenue	During the three months ended March 31, 2019 and 2018, regional revenue based on customer locations which each comprised greater than 10% of our total revenues, consisted of the following : Three Months Ended March 31, 2019 2018 United States 60 % 53 % Italy 23 % 15 % Korea 10 % 11 % Singapore — % 12 %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets Measured on Recurring Basis	Assets measured at fair value on a recurring basis are as follows (in thousands): Total Level 1 Level 2 Level 3 March 31, 2019 (unaudited): Money market funds $ 31,335 $ 31,335 $ — $ — December 31, 2018: Money market funds $ 4,156 $ 4,156 $ — $ —

Selected Balance Sheet Detail (

Selected Balance Sheet Detail (Tables)	3 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Inventories	Inventories consisted of the following (in thousands): March 31, December 31, 2019 2018 Raw materials $ 791 $ 791 Work in process 2,512 3,055 Finished goods 2,705 2,089 6,008 5,935 Allowance for excess and obsolete inventory and impairment charge (4,406 ) (2,685 ) Inventories, net $ 1,602 $ 3,250
Schedule of Property and Equipment	Property and equipment consisted of the following (in thousands): March 31, December 31, 2019 2018 Laboratory equipment $ 2,482 $ 2,482 Computer hardware and software 1,493 1,456 Leasehold improvements 298 298 Furniture, fixtures and equipment 46 46 4,319 4,282 Accumulated depreciation and amortization (3,356 ) (3,257 ) Property and equipment, net $ 963 $ 1,025
Schedule of Contract Liabilities	Contract liabilities consisted of the following (in thousands): Beginning balance as of December 31, 2018 $ 167 Consideration received in advance of revenue recognition 51 Revenue recognized — Ending Balance as of March 31, 2019 $ 218
Schedule of Allowance for Doubtful Accounts	Allowance for doubtful accounts consisted of the following (in thousands): Beginning balance as of December 31, 2018 $ 181 Additions — (Write-offs) Recoveries (1 ) Ending Balance as of March 31, 2019 $ 180
Schedule of Lease Assets and Liabilities	Lease assets and liabilities consisted of the following (in thousands): Assets Classification March 31, Non-current assets Right-of-use assets $ 2,508 Liabilities Current Current operating lease liabilities $ 210 Long term Long term operating lease liabilities $ 2,586
Schedule of Lease Costs	: The components of lease expense for the three months ended March 31, 2019 were as follows (unaudited): For the three months ended Lease expense: Operating lease expense $ 123 Short-term lease expense — Total lease expense $ 123 Other information: Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 117 For operating lease: Weighted average remaining lease term (in years) 7.9 Weighted average discount rate 10 %
Schedule of Minimum Future Payments	Minimum future payments under the Company’s leases at March 31, 2019 and their application to the corresponding lease liabilities are as follows (unaudited): Discounted lease Payments due 2019 (remaining nine months) $ 155 $ 359 2020 237 491 2021 277 505 2022 322 521 2023 352 516 Thereafter 1,453 1,704 Total $ 2,796 $ 4,096

Equity Securities (Tables)

Equity Securities (Tables)	3 Months Ended
	Mar. 31, 2019
Stockholders Equity Note [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	As of March 31, 2019 and 2018, we excluded the potentially dilutive securities summarized below, which entitle the holders thereof to potentially acquire shares of common stock, from our calculations of net loss per share and weighted average common shares outstanding, as their effect would have been anti-dilutive (in thousands). March 31, 2019 2018 Common stock warrants issued to underwriter of initial public offering 802 802 Common stock warrants issued in connection with March 2017 rights offering 13,647 13,647 Common stock warrants issued in connection with February 2019 rights offering 47,812 — Common stock options 8,587 7,921 Common stock issuable — 116 Restricted stock units 513 71 Employee stock purchase plan 451 229 71,812 22,786

Warrants (Tables)

Warrants (Tables)	3 Months Ended
	Mar. 31, 2019
Warrants And Rights Note Disclosure [Abstract]
Summary of Warrant Activity	A summary of warrants activity for the three months ended March 31, 2019 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Warrants outstanding as of December 31, 2018 14,449 $ 2.01 3.10 Issued 47,812 1.47 Exercised — Forfeited or expired — Warrants outstanding as of March 31, 2019 62,261 $ 1.60 4.90 Warrants exercisable as of March 31, 2019 62,261 $ 1.60 4.90

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	A summary of stock option activity under our 2011 Equity Incentive Plan (“2011 Plan”) for the three months ended March 31, 2019 is presented below (in thousands, except per share and contractual life data). Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (in Years) Options outstanding as of December 31, 2018 7,120 $ 3.83 6.81 Granted 2,103 $ 0.78 Exercised — $ Forfeited or expired (636 ) $ 3.99 Options outstanding as of March 31, 2019 8,587 $ 3.07 7.77 Options exercisable as of March 31, 2019 3,357 $ 5.26 5.76
Summary of Restricted Stock Unit (RSU) Activity	The following table summarizes restricted stock unit (“RSU”) activity for the three months ended March 31, 2019 (in thousands, except per share data): Number of Shares Weighted Average Grant Date Fair Value Per Share Outstanding as of December 31, 2018 35 $ 12.43 Awarded 527 0.75 Vested and released (49 ) 3.66 Forfeited/canceled — — Outstanding as of March 31, 2019 513 $ 1.28
Stock-based Compensation Expense	Stock-based compensation expense recognized for stock-based awards in the condensed consolidated statements of operations for the three months ended March 31, 2019 and 2018 was as follows (in thousands): Three Months Ended March 31, 2019 2018 Cost of sales $ 47 $ 65 Research and development 187 103 Clinical and regulatory 34 92 Selling and marketing 130 123 General and administrative 500 902 $ 898 $ 1,285

Organization and Business Ope_2

Organization and Business Operations - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands

Feb. 22, 2019

Jan. 25, 2019

Feb. 28, 2019

Dec. 31, 2018

Oct. 31, 2018

Aug. 31, 2018

May 31, 2018

Nov. 30, 2017

Feb. 28, 2018

Mar. 31, 2019

Mar. 31, 2018

Dec. 31, 2018

Mar. 31, 2019

Organization And Business Operations [Line Items]

Net sales

$ 1,128

$ 976

$ 6,900

Type of Revenue [Extensible List]

us-gaap:ProductMember

us-gaap:ProductMember

Closing bid price of common stock

$ 1

At Market Issuance Sales Agreement [Member]

Organization And Business Operations [Line Items]

Proceeds from issuance or sale of equity, total

$ 4,000

$ 4,000

Sale of Stock, commission paid to agents, percentage of gross proceeds

3.00%

Issuance of shares of common stock in connection with ATM, net of expenses (in shares)

2,200

0

Right Offering [Member]

Organization And Business Operations [Line Items]

Proceeds from issuance or sale of equity, total

$ 34,600

$ 34,400

Number of shares issued upon right offering

47,800,000

Share price (in dollars per share)

$ 0.724

Warrants to purchase shares of common stock

1

47,812,371

Number of securities called by each warrant or right

1

Exercise price of exercisable warrant

$ 1.47

$ 1.47

Entities Beneficially Owned by Mr. Gregg Williams [Member] | Stock Purchase Agreement [Member]

Organization And Business Operations [Line Items]

Proceeds from issuance or sale of equity, total

$ 3,000

$ 4,000

$ 5,000

$ 10,000

Entities Beneficially Owned by Mr. Gregg Williams [Member] | Right Offering [Member]

Organization And Business Operations [Line Items]

Proceeds from issuance or sale of equity, total

$ 30,000

Number of shares issued upon right offering

41,400,000

Second Sight (Switzerland) Sarl [Member]

Organization And Business Operations [Line Items]

Noncontrolling interest, ownership percentage by parent

99.50%

99.50%

Second Sight (Switzerland) Sarl [Member] | Executive Officer [Member]

Organization And Business Operations [Line Items]

Noncontrolling interest, ownership percentage by noncontrolling owners

0.50%

0.50%

Summary of Significant Accounti

Summary of Significant Accounting Policies (Details) - USD ($)	May 10, 2019	Mar. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Impairment charge		$ 2,424,000
Right-of-use assets		2,508,000	$ 2,600,000
Operating Lease, Liability		2,796,000	2,800,000
Adjustment of difference between right-of-use assets and operating lease liabilities				$ (144,000)
ASU No 2016-02 [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Adjustment of difference between right-of-use assets and operating lease liabilities			$ 200,000
Argus II Product [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Impairment charge		2,400,000
Other assets impairment charge		$ 0
Subsequent Event [Member] | Argus II Product [Member]
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Impairment charge	$ 2,400,000
Other assets impairment charge	$ 0

Concentration of Risk - Schedul

Concentration of Risk - Schedule of Revenues by Customer Type (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Concentration Risk [Line Items]
Revenue	$ 1,128	$ 976	$ 6,900
Direct Channel [Member]
Concentration Risk [Line Items]
Revenue	946	659
Indirect Channel [Member]
Concentration Risk [Line Items]
Revenue	$ 182	$ 317

Concentration of Risk - Sched_2

Concentration of Risk - Schedule of Concentration of Risk (Details) - Customer Concentration Risk [Member]	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Customer 1 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	23.00%	15.00%
Customer 1 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer concentration	28.00%
Customer 2 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	15.00%	14.00%
Customer 2 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer concentration	24.00%		22.00%
Customer 3 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	13.00%
Customer 3 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer concentration	23.00%		21.00%
Customer 4 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	12.00%
Customer 4 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer concentration	22.00%
Customer 5 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	12.00%
Customer 5 [Member] | Accounts Receivable [Member]
Concentration Risk [Line Items]
Customer concentration			55.00%
Customer 6 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	10.00%	11.00%
Customer 7 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration	10.00%
Customer 8 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration		22.00%
Customer 9 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration		12.00%
Customer 10 [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Customer concentration		11.00%

Concenration of Risk - Schedule

Concenration of Risk - Schedule of Geographic Concentration of Risk in Revenue (Details)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
UNITED STATES
Concentration Risk [Line Items]
Geographic concentration	60.00%	53.00%
ITALY
Concentration Risk [Line Items]
Geographic concentration	23.00%	15.00%
KOREA
Concentration Risk [Line Items]
Geographic concentration	10.00%	11.00%
SINGAPORE
Concentration Risk [Line Items]
Geographic concentration		12.00%

Concentration of Risk - Additio

Concentration of Risk - Additional Information (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Concentration Risk [Line Items]
Assets	$ 38,548	$ 10,682
Second Sight (Switzerland) Sarl [Member]
Concentration Risk [Line Items]
Assets	$ 1,500	$ 1,500

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value on a Recurring Basis (Details) - Money Market Funds [Member] - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Money market funds	$ 31,335	$ 4,156
Level 1 [Member]
Money market funds	$ 31,335	$ 4,156

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions	Mar. 31, 2019	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Deposit account	$ 0.2	$ 0.2

Selected Balance Sheet Detail -

Selected Balance Sheet Detail - Schedule of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Raw materials	$ 791	$ 791
Work in process	2,512	3,055
Finished goods	2,705	2,089
Inventories, gross	6,008	5,935
Allowance for excess and obsolete inventory and impairment charge	(4,406)	(2,685)
Inventories, net	$ 1,602	$ 3,250

Selected Balance Sheet Detail_2

Selected Balance Sheet Detail - Additional Information (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Product Information [Line Items]
Impairment charge	$ 2,424
Operating lease, renewal term	5 years
Incremental borrowing rate	10.00%
Argus II Product [Member]
Product Information [Line Items]
Impairment charge	$ 2,400

Selected Balance Sheet Detail_3

Selected Balance Sheet Detail - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 4,319	$ 4,282
Accumulated depreciation and amortization	(3,356)	(3,257)
Property and equipment, net	963	1,025
Laboratory Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,482	2,482
Computer Hardware and Software [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,493	1,456
Leasehold Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	298	298
Furniture, Fixtures and Equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 46	$ 46

Selected Balance Sheet Detail_4

Selected Balance Sheet Detail - Schedule of Contract Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Revenue From Contract With Customer [Abstract]
Beginning balance as of December 31, 2018	$ 167
Consideration received in advance of revenue recognition	51
Ending Balance as of March 31, 2019	$ 218

Selected Balance Sheet Detail_5

Selected Balance Sheet Detail - Schedule of Allowance for Doubtful Accounts (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Allowance for Doubtful Accounts Receivable [Roll Forward]
Beginning balance as of December 31, 2018	$ 181
(Write-offs) Recoveries	(1)
Ending Balance as of March 31, 2019	$ 180

Selected Balance Sheet Detail_6

Selected Balance Sheet Detail - Schedule of Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 01, 2019
Assets
Non-current assets, Right-of-use assets	$ 2,508	$ 2,600
Liabilities
Current, Current operating lease liabilities	210
Long term, Long term operating lease liabilities	$ 2,586

Selected Balance Sheet Detail_7

Selected Balance Sheet Detail - Schedule of Lease Costs (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Lease expense:
Operating lease expense	$ 123
Total lease expense	123
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 117
For operating lease:
Weighted average remaining lease term (in years)	7 years 10 months 24 days
Weighted average discount rate	10.00%

Selected Balance Sheet Detail_8

Selected Balance Sheet Detail -Schedule of Minimum Future Payments and Corresponding Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 01, 2019
Operating Discounted Lease Liabilities Payments Due [Abstract]
2019 (remaining nine months)	$ 155
2020	237
2021	277
2022	322
2023	352
Thereafter	1,453
Total	2,796	$ 2,800
Operating Lease Liabilities, Payments Due [Abstract]
2019 (remaining nine months)	359
2020	491
2021	505
2022	521
2023	516
Thereafter	1,704
Total	$ 4,096

Equity Securities - Anti-diluti

Equity Securities - Anti-dilutive Securities (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	71,812	22,786
Underwriter's With Initial Public Offering
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	802	802
Warrants Issued in Connection With March 2017 Rights Offering
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	13,647	13,647
Warrants Issued in Connection With February 2019 Rights Offering
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	47,812
Common Stock Options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	8,587	7,921
Common Stock Issuable
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)		116
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	513	71
Employee Stock Purchase Plan
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities (in shares)	451	229

Warrants - Additional Informati

Warrants - Additional Information (Details) $ / shares in Units, $ in Millions	Feb. 15, 2019shares	Mar. 31, 2019USD ($)$ / shares	Feb. 28, 2019$ / sharesshares	Feb. 22, 2019$ / sharesshares	Dec. 31, 2018$ / shares
Risk Free Interest Rate
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input		0.0249
Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input		0.82
Expected Lives [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input		5 years 29 days
Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input		0
Common Stock [Member]
Class Of Warrant Or Right [Line Items]
Warrants exercise price		$ 2.94
Share price		0.47
Warrant
Class Of Warrant Or Right [Line Items]
Warrants exercise price		$ 1.60			$ 2.01
Description for redemption of warrants		the warrants are redeemable on 30 days’ notice (i) if, after March 14, 2019, the shares of the Company’s common stock are trading at $2.94 for 15 consecutive trading days and (ii) if all of the independent directors vote in favor of redeeming the warrants. Holders may be able to sell or exercise warrants prior to any announced redemption date and the Company will redeem outstanding warrants not exercised by the announced redemption date for a nominal amount of $0.01 per Warrant.
Class of warrant or right outstanding redemption price of warrants or rights		$ 0.01
Share price		$ 0.25
March 2017 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Number of warrants issued | shares	13,647,286
Adjustment to additional paid-in capital and accumulated deficit | $		$ 1.6
March 2017 Warrants Before Extension [Member] | Risk Free Interest Rate
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	2.50
March 2017 Warrants Before Extension [Member] | Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	81
March 2017 Warrants Before Extension [Member] | Expected Lives [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	3 years 29 days
March 2017 Warrants Before Extension [Member] | Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	0
March 2017 Warrants After Extension [Member] | Risk Free Interest Rate
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	2.49
March 2017 Warrants After Extension [Member] | Expected Volatility [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	82
March 2017 Warrants After Extension [Member] | Expected Lives [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	5 years 29 days
March 2017 Warrants After Extension [Member] | Dividend Yield [Member]
Class Of Warrant Or Right [Line Items]
Alternative investment, measurement input	0
Right Offering [Member]
Class Of Warrant Or Right [Line Items]
Warrants to purchase shares of common stock | shares			47,812,371	1
Warrants exercise price			$ 1.47	$ 1.47
Share price				$ 0.724
Right Offering [Member] | March 2017 Warrants [Member]
Class Of Warrant Or Right [Line Items]
Term of warrants	2 years

Warrants - Summary of Warrants

Warrants - Summary of Warrants Activity (Details) - Warrant - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Class of Warrant or Right, Outstanding [Roll Forward]
Outstanding at beginning	14,449,000
Issued	47,812,000
Outstanding at ending	62,261,000	14,449,000
Exercisable at ending	62,261,000
Class of Warrant or Right, Exercise Price of Warrants or Rights [Roll Forward]
Outstanding at beginning	$ 2.01
Issued	1.47
Outstanding at ending	1.60	$ 2.01
Exercisable at ending	$ 1.60
Class of Warrant or Right, Weighted Average Remaining Contractual Life of Warrants or Rights [Roll Forward]
Outstanding at ending	4 years 10 months 24 days	3 years 1 month 6 days
Exercisable at ending	4 years 10 months 24 days

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - 2011 Equity Incentive Plan - Employee Stock Option - $ / shares shares in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options outstanding, number of shares (in shares)	7,120
Granted, number of shares (in shares)	2,103
Forfeited or expired, number of shares (in shares)	(636)
Options outstanding, number of shares (in shares)	8,587	7,120
Options exercisable, number of shares (in shares)	3,357
Options outstanding, weighted average exercise price (in dollars per share)	$ 3.83
Granted, weighted average exercise price (in dollars per share)	0.78
Forfeited or expired, weighted average exercise price (in dollars per share)	3.99
Options outstanding, weighted average exercise price (in dollars per share)	3.07	$ 3.83
Options exercisable, weighted average exercise price (in dollars per share)	$ 5.26
Options outstanding, weighted average remaining contractual life (Year)	7 years 9 months 7 days	6 years 9 months 21 days
Options exercisable, weighted average remaining contractual life (Year)	5 years 9 months 3 days

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details)	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Restricted Stock Units (RSUs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 8 months 23 days
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.75
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options | $	$ 600,000
Awarded, number of awards (in shares) | shares	526,500
2011 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of stock options exercisable | $	$ 1,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $	$ 4,400,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years 7 days
2011 Equity Incentive Plan | Certain Employees and Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares	2,102,862
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value | $	$ 1,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	72.00%
2011 Equity Incentive Plan | Certain Employees and Directors | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.69
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.45
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 7 days
2011 Equity Incentive Plan | Certain Employees and Directors | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.87
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.57
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years 29 days
2011 Equity Incentive Plan | Employee Stock Option
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares	2,103,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.78
2011 Equity Incentive Plan | Employee Stock Option | Certain Employees and Directors
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
2011 Equity Incentive Plan | Employee Stock Option | Certain Employees and Directors | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.51%
2011 Equity Incentive Plan | Employee Stock Option | Certain Employees and Directors | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.63%
The 2015 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares	2,050,000

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Restricted Stock Unit (RSU) Activity (Details) - Restricted Stock Units (RSUs)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding, number of awards (in shares) | shares	35,000
Awarded, number of awards (in shares) | shares	526,500
Vested and released (in shares) | shares	(49,000)
Outstanding, number of awards (in shares) | shares	513,000
Outstanding, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 12.43
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares	0.75
Vested and released, weighted average grant date fair value per share (in dollars per share) | $ / shares	3.66
Outstanding, weighted average grant date fair value per share (in dollars per share) | $ / shares	$ 1.28

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Allocated share-based compensation expense	$ 898	$ 1,285
Cost of Sales
Allocated share-based compensation expense	47	65
Research and Development
Allocated share-based compensation expense	187	103
Clinical and Regulatory
Allocated share-based compensation expense	34	92
Selling and Marketing
Allocated share-based compensation expense	130	123
General and Administrative
Allocated share-based compensation expense	$ 500	$ 902

Subsequent Events - Additional

Subsequent Events - Additional Information (Details)	May 10, 2019USD ($)Employee	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)
Subsequent Event [Line Items]
Impairment charge			$ 2,424,000
Argus II Product [Member]
Subsequent Event [Line Items]
Impairment charge			2,400,000
Other assets impairment charge			$ 0
Scenario Forecast [Member]
Subsequent Event [Line Items]
Restructuring charges, total		$ 700,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Restructuring and related cost, number of positions eliminated | Employee	21
Subsequent Event [Member] | Argus II Product [Member]
Subsequent Event [Line Items]
Impairment charge	$ 2,400,000
Other assets impairment charge	$ 0